All Episodes
Business Trip — 69 episodes
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Virtual Mitochondrial Models and the Case for Engineering Humans with Mariëlle van Kooten
Brain Organoids: from Space to AI with Alysson Muotri
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Inside Philanthropy’s Role in Mental & Brain Health
Rick Perry on paving the way for Ibogaine in America
Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute
AI and the future of therapy with Luis Voloch of Jimini Health
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
Transforming Skin Cells into Neurons to Treat Alzheimer’s with Brendon Boot of Skin2Neuron
Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia
The 4-Hour Sleepers Redefining Human Limits with Ying-Hui Fu of UCSF
What's wrong with US healthcare and how startups can fix it, with Justin Mares
Temporal Interference: The Future of Brain Stimulation with Nir Grossman
The State of Autism Part 2 with James Adams of Gut-Brain-Axis Therapeutics Inc.
The State of Autism Part 1 with Elizabeth Horn of 2m Foundation
Genetic Medicine for Brain Health with Dana Watt of Breakout Ventures
Transcranial Focused Ultrasound for Mental Health with Jay Sanguinetti of Sanmai
Navigating FDA clinical trials in Neurotech with Tim Marjenin
Environmental Toxins and Mental Health with Gurdane Bhutani
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Investing in New Frontiers of Mental Health (Live at SXSW)
Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF)
What Payers Want with Lili Brillstein
Decoding the Brain with Ed Boyden
5-MeO-DMT in mental healthcare with Steve Rio
Tom Insel: Startups, AI, Psychedelics, and SSRIs
Food as Medicine for Mental Health: Drew Ramsey
Ketogenic Diet for Brain Health: Jan Baszucki
Investing in Neurotech 101: Alex Morgan of Khosla Ventures
All you need is d̶r̶u̶g̶s̶ energy: Motif Neurotech's Implants for Depression
Holy poop! Mental health and the gut (part 2 with Bloom Science)
Holy poop! Mental health and the gut (part 1 with Holobiome)
Ketamine for OCD: Carolyn Rodriguez (Stanford pt 3)
Are psychedelics effective under anesthesia?: Boris Heifets (Stanford pt 2)
The Startup Landscape for Expanding Consciousness
Stanford Psychedelic Overview: Robert Malenka (Stanford pt 1)
Live from Psychedelic Science 2023
What VCs Look for in Psychedelic Companies
Developing Non-Hallucinogenic Psychedelics: Bryan Roth
Behind the Scenes of PsyMed Ventures
The 2023 Psychedelic Industry Landscape with Psychedelic Alpha
The State of Psychedelics (Part 2): Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
The quest to improve MDMA
Transcranial magnetic stimulation (TMS) paired with ketamine: inside a clinic offering a frontier treatment
Perspectives from Christian Angermayer, investor and founder in psychedelics
Soltara: an ethical and profitable ayahuasca retreat
Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics
Microdosing (part 2): Placebo is a hell of a drug with Balázs Szigeti
Microdosing (part 1): James Fadiman and the fundamentals of microdosing
How the DEA and FDA will regulate psychedelic medicine
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
Empowering the next wave of psychedelic therapists: Journey Clinical
Osmind and the future of electronic health records in psychedelic medicine
Palo Santo on investing in 2nd gen psychedelics and public markets
Designing psychedelic mindstates, with Mindstate Design Labs
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy
On transformational ketamine therapy and running an integrative psychedelic clinic
The new frontiers of DMT therapies
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
Analyzing the atai Life Sciences IPO
A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx
Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney
How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka
From serving medicine to company founder: NANA founder Flor Bollini
Helping psychedelic practitioners through software: Maya Health CEO David Champion
How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer
Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin
Dylan Beynon: ketamine-assisted therapy for anxiety and depression